Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Higher-risk myelodysplastic syndromes, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing has beaten azacitidine alone in a phase 3 trial.
TP53 multi-hit disease relapses after transplant and responds to no drug durably.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Post-transplant maintenance to prevent relapse is unproven.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Three-year overall survival 47.
A milestone in how this cancer is treated.